Human papilloma virus infection in HIV-infected women in Belgium: implications for prophylactic vaccines within this subpopulation


Although high-risk (HR) human papilloma virus (HPV) infection is the primary causative factor for cervical squamous intraepithelial lesions and invasive cervical cancer, the epidemiology of potentially HR (pHR) and low-risk HPV still remains to be elucidated in HIV-infected women. In addition, the synergistic potential of the multiplicity of HPV infections harboured renders it difficult to model the impact of vaccines. This cross-sectional analysis of HIV-infected women explores the epidemiology of abnormal cytology, thereby profiling and pairing pHR/HR HPV genotypes. This cross-sectional analysis reports the findings of 593 HIV-infected women, who underwent a cytological examination and HPV genotyping. A logistic regression model was fitted to adjust for age and coinfection with pHR/HR HPV genotypes. In the 143 women with abnormal cytology, a multiple pHR/HR HPV genotype prevalence of 64.1% [95% confidence interval (CI): 44.6-57.6%] was observed. A combined prevalence of HPV 16 and HPV 18 of 29.6% (95% CI: 22.2-37.8%) was found. HPV 6 and HPV 66 were found in two cases of low-grade squamous intraepithelial lesions as stand-alone genotypes and HPV 53 in a high-grade squamous intraepithelial lesion case. Pairing involving HPV 31 with HPV 16 and HPV 58 was found in high-grade squamous intraepithelial lesion cases. Significant associations were observed between abnormal cytology, multiple HPV, HPV 39 and HPV 53 [adjusted odds ratio (aOR): 2.02; P=0.01; 95% CI: 1.2-3.5; aOR: 3.8; P=0.01; 95% CI: 1.4-10.7; and aOR: 0.5; P=0.03; 95% CI: 0.2-0.9, respectively]. Coinfection with pHR/HR HPV genotypes HPV 39 and 53 was significantly associated with abnormal cytology. Research into the imputed role of HPV 31 in pairings, low-risk and pHR HPV genotypes in HIV-infected women is warranted.


Authors & affiliation: 
By:Menon, S (Menon, Sonia)[ 1 ] ; Rossi, R (Rossi, Rodolfo)[ 2 ] ; Benoy, I (Benoy, Ina)[ 2 ] ; Bogers, JP (Bogers, Jean P.)[ 1,3,4 ] ; van den Broeck, D (van den Broeck, Davy)[ 1,3,4 ] [ 1 ] Univ Ghent, Int Ctr Reprod Hlth, Dept Obstet & Gynaecol, Ghent, Belgium [ 2 ] AMBIOR Appl Mol Biol Res Grp, Brussels, Belgium [ 3 ] Natl Reference Ctr HPV, Brussels, Belgium [ 4 ] AML, Lab Mol Pathol, Antwerp, Belgium
Staff Members: 
Published In: 
European Journal of Cancer Prevention 2018, Vol 27 No 1
Publication date: 
Wednesday, January 31, 2018